High-Precision Risk Stratification: Beyond Traditional Biomarkers
Cardiovascular disease (CVD) remains the leading cause of global morbidity and mortality, necessitating constant refinement of risk assessment tools. For decades, clinical practice has relied on traditional risk factors—age, sex, smoking status, blood pressure, and lipid profiles—to guide primary prevention. In Europe, the Systematic Coronary Risk Evaluation 2 (SCORE2) serves as the gold standard for predicting the 10-year risk of fatal and non-fatal cardiovascular events. However, a significant proportion of cardiovascular events occur in individuals classified as ‘low’ or ‘intermediate’ risk by these standard models. This residual risk suggests that current tools fail to capture the complex interplay of genetic predisposition and metabolic dysregulation.
A landmark study by Ritchie et al., recently published in the European Heart Journal, provides a compelling solution. By integrating nuclear magnetic resonance (NMR) metabolomics and polygenic risk scores (PRS) into the existing SCORE2 framework, researchers have demonstrated a substantial improvement in risk discrimination and stratification. This multi-omic approach not only identifies high-risk individuals more accurately but also offers a blueprint for how precision medicine can be implemented at a population scale.
